February 3, 2011

For Immediate Release

# Sumitomo Chemical Reports Consolidated Financial Results For the Nine Months Ended December 31, 2010

The Sumitomo Chemical Group's sales for the nine months ended December 31, 2010 were ¥1,466.6 billion, an increase of ¥323.9 billion compared with the same period of the previous year. The Group's operating income was ¥79.3 billion, ordinary income was ¥76.4 billion and net income was ¥14.1 billion, all representing year-on-year increases.

During the nine months ended December 31, 2010, the Group posted an extraordinary loss of ¥32.5 billion due mainly to a one-time amortization of goodwill at the end of the second quarter related to its investment in an affiliate, the fair value of which significantly declined.

The Sumitomo Chemical Group's financial results by business segment for the nine month period are as follows.

### Basic Chemicals

Sales of raw materials for synthetic fibers, such as caprolactam, and methyl methacrylate expanded because of a rise in market prices and an increase in shipments in Asia. Sales of aluminum increased due to higher market prices and a recovery in demand. As a result, the segment's sales expanded by ¥39.3 billion over the same period of the previous year, to ¥182.9 billion, and operating income improved by ¥16.5 billion, to a profit of ¥15.9 billion.

#### Petrochemicals & Plastics

Sales of synthetic resins and petrochemical products increased because of a substantial increase in shipments by sales subsidiaries due to the full-fledged contribution of the Rabigh complex, which started operation in April 2009, as well as higher selling prices in Japan and higher market prices overseas resulting from a rise in prices for naphtha and other feedstocks. Consequently, the segment's sales increased by ¥140.2 billion over the same period of the previous year, to ¥477.8 billion, and operating income improved by ¥13.8 billion, to a profit of ¥10.0 billion.

#### Fine Chemicals

Sales of raw materials for adhesives increased due to a recovery in demand and sales promotion efforts. As a result, the segment's sales rose by 4.4 billion over the same period of the previous year, to 466.9 billion, and operating income improved by 40.6 billion, to 41.5 billion.

#### IT-related Chemicals

Sales of polarizing film used in liquid crystal displays grew because of a significant increase in shipments, spurred by strong demand in Korea, Taiwan, and China. As a result, the segment's sales rose by  $\pm 58.2$  billion from the same period of the previous year, to  $\pm 247.6$  billion, and operating income improved by  $\pm 24.5$  billion, to  $\pm 25.9$  billion.

#### Agricultural Chemicals

Shipments of feed additive methionine and of the long-lasting insecticidal mosquito net, OLYSET® Net, increased steadily. In the area of crop protection chemicals, shipments of herbicides continued to be solid in overseas markets. As a result, the segment's sales increased by ¥3.0 billion from the same period of the previous year, to ¥153.1 billion. Operating income, however, declined by ¥2.6 billion, to ¥15.6 billion, owing to a decrease in export sales in yen terms due to the appreciation of the yen and increased fixed costs resulting from capacity expansion.

#### **Pharmaceuticals**

Sales of Amlodin® (therapeutic agent for hypertension and angina pectoris) declined because of Japanese National Health Insurance drug price revisions and competition with generic drugs. Sales of Avapro® (therapeutic agent for hypertension), Lonasen® (therapeutic agent for schizophrenia), the new drug Trerief® (therapeutic agent for Parkinson's disease), and other new pharmaceuticals increased as a result of continued sales promotion efforts. Sunovion Pharmaceuticals Inc. (Sunovion changed its name from Sepracor Inc. in October 2010) and other U.S. subsidiaries, which became consolidated subsidiaries as of the end of the third quarter of the previous fiscal year, also contributed to the segment's performance. As a result, the segment's sales increased by ¥88.3 billion from the same period of the previous year, to ¥270.1 billion. Operating income declined by ¥3.1 billion, to ¥24.8 billion, because of amortization expenses of patent rights and other intangible assets associated with the acquisition of Sunovion.

#### Others

In addition to the above six segments, the Sumitomo Chemical Group engages in supplying electrical power and steam, providing services for the design, engineering and construction management of chemical plants, providing transport and warehousing, and conducting materials and environmental analysis. The segment's sales decreased by ¥9.5 billion from the same period of the previous year, to ¥68.2 billion, but operating income remained flat at ¥3.2 billion.

(Note) Changes in the operating income calculation and business classification methods

The Company has been applying the Accounting Standard for Disclosures about Segments of an Enterprise and Related Information (ASBJ Statement No. 17 of March 27, 2009) and the Implementation Guidance on Accounting Standard for Disclosures about Segments of an Enterprise and Related Information (ASBJ Guidance No. 20 of March 21, 2008) from the nine months ended December 31, 2010. Along with this, the method for allocating shared company-wide research expenses and other expenses has been revised, and the business segment categorization of consolidated subsidiaries has been changed. For the purpose of comparison, the figures for the nine months ended December 31, 2009 have also been adjusted to reflect these accounting changes.

## **Summary of Consolidated Results**

#### (1) Results of Operations: 9 Months ended 9 Months ended December 31, 2010 December 31, 2009 ¥ Million US\$ 1,000 ¥ Million ) ( ) ( ) Net sales ¥ ¥ 1,466,554 \$ 17,996,736 1,142,661 79,266 29,833 Operating income 972,708 Ordinary income 76,352 936,949 19,646 Income before income taxes and minority interests 43,870 24,016 538,348 Net income 14,135 173,457 1,226 )\*1 US\$ ( Yen ) ( ( Yen ) ¥ ¥ Net income per 1,000 shares 8,580 \$ 105 743

(2) Financial Position:	As of December 31, 2010			As of March 31, 2010	
	(	¥ Million )	(US\$ 1,000) <sup>*1</sup>	(¥ Million)	
Total assets	¥	2,304,443	\$ 28,278,844	¥ 2,383,906	
Total net asset		758,568	9,308,725	821,436	
	(	Yen )	( US\$ ) <sup>*1</sup>	(Yen)	
Book value per 1,000 shares	¥	317,818	\$ 3,900	¥ 348,525	

(3) Cash Flows:	9 Months ended December 31, 2010			9 Months ended December 31, 2009	
	(	¥ Million )	(US\$ 1,000) <sup>*1</sup>	( ¥ Million )	
Cash flows from operating activities	¥	116,058	\$ 1,424,199	¥ 83,373	
Cash flows from investing activities		(121,057)	(1,485,544)	(268,057)	
Cash flows from financing activities		31,072	381,298	236,902	
Cash and cash equivalents at end of period		140,503	1,724,175	139,041	

(4) Results of Operations by Business Segment:	9 Months ended December 31, 2010				-	9 Months ended December 31, 2009	
-	(	¥ Million )	(	US\$ 1,000 ) <sup>*1</sup>	(	¥ Million ) <sup>*2</sup>	
Net sales							
Basic Chemicals	¥	182,946	\$	2,245,012	¥	143,633	
Petrochemicals & Plastics		477,816		5,863,492		337,592	
Fine Chemicals		66,853		820,383		62,423	
IT-related Chemicals		247,590		3,038,287		189,437	
Agricultural Chemicals		153,080		1,878,513		150,075	
Pharmaceuticals		270,092		3,314,419		181,797	
Others		68,177		836,630		77,704	
	¥	1,466,554	\$	17,996,736	¥	1,142,661	
Operating income							
Basic Chemicals	¥	15,890	\$	194,993	¥	(647)	
Petrochemicals & Plastics		9,996		122,665		(3,783)	
Fine Chemicals		1,537		18,861		915	
IT-related Chemicals		25,930		318,199		1,421	
Agricultural Chemicals		15,595		191,373		18,209	
Pharmaceuticals		24,835		304,761		27,927	
Others		3,192		39,170		3,219	
Adjustments		(17,709)		(217,314)		(17,428)	
	¥	79,266	\$	972,708	¥	29,833	

(Note)

\*1:U.S. dollar amounts are translated from yen, for convenience only, at the rate of

¥81.49= \$1 prevailing on December 31, 2010.

\*2:unaudited amount having been reclassified according to new segmentation